| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health |
ChiCTR2200058811: Establishment of a Nomogram model to predict portal vein thrombosis in cirrhosis and clinical study of its intervention |
|
|
| Not yet recruiting | 1 | 200 | | Rifaximin (standard dose 200mg/ time, three times a day, for 14 days) + conservative treatment according to the condition ;Conservative treatment according to the condition | The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, None | Cirrhosis of the liver | | | | |
NCT06298409: Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® |
|
|
| Recruiting | 1 | 34 | US | CapScan collection capsule | Envivo Bio Inc | Small Intestinal Bacterial Overgrowth | 06/25 | 07/25 | | |
NCT03820817: Rifaximin in Patients With Monoclonal Gammopathy |
|
|
| Recruiting | 1 | 48 | US | Rifaximin, Xifaxan | Emory University, The Leukemia and Lymphoma Society | IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy, Light Chain Deposition Disease, Monoclonal Gammopathy, Smoldering Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia, Gammopathy, Monoclonal, Gammopathy Igg | 11/25 | 11/25 | | |
NCT05159427: Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers |
|
|
| Recruiting | 1 | 40 | US | Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab, 13C6-Glipizide, Stable Isotope Glipizide | University of Michigan, Food and Drug Administration (FDA) | Human Gastrointestinal Physiology Data | 09/26 | 09/26 | | |
| Recruiting | 1 | 124 | RoW | Rifaximin 200 mg, Standard Treatment without Rifaximin | Sun Yat-sen University | Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV, Hepatitis B, Rifaximin, Effect of Drug | 07/25 | 10/25 | | |
